 <h1>Lupaneta Pack Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>leuprolide / norethindrone</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about leuprolide / norethindrone. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Lupaneta Pack.</p><h2>In Summary</h2><p><b>Common side effects of Lupaneta Pack include:</b> depression and migraine.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to leuprolide/norethindrone: powder for suspension 1 month, powder for suspension 3 month, tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, leuprolide / norethindrone may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking leuprolide / norethindrone:</p><p>
<i>More common</i>
</p><ul>
<li>Crying</li>
<li>depersonalization</li>
<li>dysphoria</li>
<li>euphoria</li>
<li>feeling of warmth</li>
<li>mental depression</li>
<li>paranoia</li>
<li>quick to react or overreact emotionally</li>
<li>rapidly changing moods</li>
<li>redness of the face, neck, arms, and occasionally, upper chest</li>
<li>sudden sweating</li>
<li>swelling</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Anxiety</li>
<li>bladder pain</li>
<li>bloody or cloudy urine</li>
<li>blurred vision</li>
<li>chest pain</li>
<li>confusion</li>
<li>convulsions</li>
<li>cough</li>
<li>dark urine</li>
<li>difficult, burning, or painful urination</li>
<li>difficulty speaking</li>
<li>difficulty swallowing</li>
<li>dizziness or lightheadedness</li>
<li>double vision</li>
<li>fainting</li>
<li>fast heartbeat</li>
<li>flu-like symptoms</li>
<li>frequent urge to urinate</li>
<li>headache</li>
<li>hives or welts</li>
<li>inability to move the arms, legs, or facial muscles</li>
<li>increased sensitivity of the skin to sunlight</li>
<li>itching</li>
<li>joint or muscle pain or stiffness</li>
<li>lower back or side pain</li>
<li>nausea and vomiting</li>
<li>numbness or tingling in the face, arms, or legs</li>
<li>pain in the groin or genitals</li>
<li>pain, redness, or swelling in the arm or leg</li>
<li>pounding in the ears</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>redness of the skin</li>
<li>right upper quadrant tenderness</li>
<li>severe sunburn</li>
<li>sharp back pain just below the ribs</li>
<li>skin rash</li>
<li>slow or fast heartbeat</li>
<li>slow speech</li>
<li>sudden shortness of breath or trouble breathing</li>
<li>sweating</li>
<li>thoughts or attempts at killing oneself</li>
<li>tightness in the chest</li>
<li>trouble breathing</li>
<li>trouble sleeping</li>
<li>trouble thinking or walking</li>
<li>unusual tiredness or weakness</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of leuprolide / norethindrone may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Acid or sour stomach</li>
<li>being forgetful</li>
<li>belching</li>
<li>bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site</li>
<li>blemishes on the skin</li>
<li>bloated or full feeling</li>
<li>burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings</li>
<li>changes in appetite</li>
<li>decreased interest in sexual intercourse</li>
<li>diarrhea</li>
<li>difficulty having a bowel movement (stool)</li>
<li>excess air or gas in the stomach or intestines</li>
<li>feeling of constant movement of self or surroundings</li>
<li>hair loss or thinning of the hair</li>
<li>headache, severe and throbbing</li>
<li>heartburn</li>
<li>inability to have or keep an erection</li>
<li>indigestion</li>
<li>lack or loss of strength</li>
<li>loss in sexual ability, desire, drive, or performance</li>
<li>pain or tenderness from the breasts</li>
<li>passing gas</li>
<li>pimples</li>
<li>sensation of spinning</li>
<li>stomach discomfort, upset, or pain</li>
<li>weight gain</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Absent missed or irregular menstrual periods</li>
<li>itching of the vagina or genital area</li>
<li>pain during sexual intercourse</li>
<li>stopping of menstrual bleeding</li>
<li>thick, white vaginal discharge with no odor or with a mild odor</li>
</ul><p>
<!-- end powder for suspension 1 month, powder for suspension 3 month, tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to leuprolide / norethindrone: oral and injectable kit</i></p><h3>General</h3><p>The most common adverse reactions leading to discontinuation of therapy included hot flashes (4%), emotional lability (4%), depression (4%) and acne (2%).</p>
<p>The most common adverse reaction observed were hot flashes and headaches.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Leuprolide-Norethindrone:</p>
<p><b>Very common</b> (10% or more): Hot flashes/sweats (up to 87%)</p>
<p></p>
<p>Leuprolide:</p>
<p><b>Very common</b> (10% or more): Hot flashes/sweats (98%)</p>
<p><b>Postmarketing reports</b>: Hypotension, hypertension, serious venous and arterial thrombotic and thromboembolic events (deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, transient ischemic attack<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Leuprolide-Norethindrone:</p>
<p><b>Very common</b> (10% or more): Androgen-like effects (acne, alopecia) (up to 18%), skin/mucous membrane reaction (up to 11%)</p>
<p></p>
<p>Leuprolide:</p>
<p><b>Common</b> (1% to 10%): Androgen-like effects (acne, alopecia) (4%), skin/mucous membrane reaction (4%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Leuprolide-Norethindrone:</p>
<p><b>Very common</b> (10% or more): Altered bowel function (constipation, diarrhea) (up to 15%), nausea/vomiting (up to 29%)</p>
<p><b>Common</b> (1% to 10%): GI disturbances (dyspepsia, flatulence) (up to 7%), changes in appetite (6%)</p>
<p></p>
<p>Leuprolide:</p>
<p><b>Very common</b> (10% or more): Nausea/vomiting (25%), altered bowel function (constipation, diarrhea) (14%)</p>
<p><b>Common</b> (1% to 10%): Changes in appetite (4%)%), GI disturbances (dyspepsia, flatulence) (4%)<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>Leuprolide-Norethindrone:</p>
<p><b>Very common</b> (10% or more): Vaginitis (up to 15%%), breast changes/pain/tenderness (up to 13%)</p>
<p><b>Common</b> (1% to 10%): Menstrual disorders (5%)</p>
<p><b>Frequency not reported</b>: Urinary tract infection</p>
<p></p>
<p>Leuprolide:</p>
<p><b>Very common</b> (10% or more): Vaginitis (20%)</p>
<p><b>Common</b> (1% to 10%): Breast changes/pain/tenderness (6%), menstrual disorders (2%)<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Leuprolide:</p>
<p><b>Postmarketing reports</b>: Decreased white blood count<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Leuprolide:</p>
<p><b>Postmarketing reports</b>: Serious liver injury</p>
<p>Leuprolide-Norethindrone:</p>
<p><b>Common</b> (1% to 10%): Elevated SGPT (at least twice the upper limit) (2%), elevated GGT (1.5%)<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Leuprolide-Norethindrone:</p>
<p><b>Postmarketing reports</b>: Allergic reactions (anaphylactic, rash, urticaria, photosensitivity)<sup>[Ref]</sup></p><h3>Local</h3><p>Leuprolide-Norethindrone:</p>
<p><b>Common</b> (1% to 10%): Injection site reaction (up to 9%)</p>
<p></p>
<p>Leuprolide:</p>
<p><b>Common</b> (1% to 10%): Injection site reaction (2%)</p>
<p><b>Postmarketing reports</b>: Localized reactions including induration and abscess at the site of injection<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Leuprolide-Norethindrone:</p>
<p><b>Very common</b> (10% or more): Weight gain (up to 13%)</p>
<p><b>Common</b> (1% to 10%): Edema (up to 9%), elevated SGPT (at least twice the upper limit) (2%), elevated GGT (1.5%)</p>
<p><b>Frequency not reported</b>: Increased total cholesterol (greater than 240 mg/dL), decreased HDL cholesterol (less than 40 mg/dL), increased LDL cholesterol (greater than 160 mg/dL), increased LDL/HDL ratio (greater than 4), increased triglycerides (greater than 200 mg/dL)</p>
<p></p>
<p>Leuprolide:</p>
<p><b>Common</b> (1% to 10%): Weight gain (12%)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Leuprolide:</p>
<p><b>Postmarketing reports</b>: Spinal fracture, tenosynovitis-like symptoms, symptoms consistent with fibromyalgia<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Leuprolide-Norethindrone:</p>
<p><b>Very common</b> (10% or more): Headache/migraine (up to 51%), insomnia/sleep disorders (up to 15%), dizziness/vertigo (up to 11%)</p>
<p><b>Common</b> (1% to 10%): Neuromuscular disorder (leg cramps, paraesthesia) (up to 9%), decreased libido (up to 7%), memory disorder (up to 4%)</p>
<p></p>
<p>Leuprolide:</p>
<p><b>Very common</b> (10% or more): Headache/migraine (65%), insomnia/sleep disorders (31%), dizziness/vertigo (16%), decreased libido (10%)</p>
<p><b>Common</b> (1% to 10%): Memory disorder (6%), neuromuscular disorder (leg cramps, paraesthesia) (2%)</p>
<p><b>Postmarketing reports</b>: Pituitary apoplexy, convulsion, peripheral neuropathy, paralysis<sup>[Ref]</sup></p><h3>Other</h3><p>Leuprolide-Norethindrone:</p>
<p><b>Very common</b> (10% or more): Pain (up to 29%), asthenia (up to 18%)</p>
<p></p>
<p>Leuprolide:</p>
<p><b>Very common</b> (10% or more): Pain (24%), asthenia (18%)</p><h3>Psychiatric</h3><p>Leuprolide-Norethindrone:</p>
<p><b>Very common</b> (10% or more): Depression/emotional lability (up to 34%), nervousness/anxiety (up to 11%)</p>
<p></p>
<p>Leuprolide:</p>
<p><b>Very common</b> (10% or more): Depression/emotional lability (31%)</p>
<p><b>Common</b> (1% to 10%): Nervousness/anxiety (8%)</p>
<p><b>Postmarketing reports</b>: Mood swings, suicidal ideation and attempt<sup>[Ref]</sup></p><h3>Renal</h3><p>Leuprolide-Norethindrone:</p>
<p><b>Frequency not reported</b>: Renal calculus<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Leuprolide:</p>
<p><b>Postmarketing reports</b>: Symptoms consistent with an asthmatic process<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Lupaneta Pack (leuprolide-norethindrone)." Abbott Pharmaceutical, Abbott Park, IL. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about Lupaneta Pack (leuprolide / norethindrone)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: sex hormone combinations</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Lupaneta Pack &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Endometriosis</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to leuprolide / norethindrone: oral and injectable kit</i></p><h3>General</h3><p>The most common adverse reactions leading to discontinuation of therapy included hot flashes (4%), emotional lability (4%), depression (4%) and acne (2%).</p><p>The most common adverse reaction observed were hot flashes and headaches.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Leuprolide-Norethindrone:</p><p><b>Very common</b> (10% or more): Hot flashes/sweats (up to 87%)</p><p></p><p>Leuprolide:</p><p><b>Very common</b> (10% or more): Hot flashes/sweats (98%)</p><p><b>Postmarketing reports</b>: Hypotension, hypertension, serious venous and arterial thrombotic and thromboembolic events (deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, transient ischemic attack<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Leuprolide-Norethindrone:</p><p><b>Very common</b> (10% or more): Androgen-like effects (acne, alopecia) (up to 18%), skin/mucous membrane reaction (up to 11%)</p><p></p><p>Leuprolide:</p><p><b>Common</b> (1% to 10%): Androgen-like effects (acne, alopecia) (4%), skin/mucous membrane reaction (4%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Leuprolide-Norethindrone:</p><p><b>Very common</b> (10% or more): Altered bowel function (constipation, diarrhea) (up to 15%), nausea/vomiting (up to 29%)</p><p><b>Common</b> (1% to 10%): GI disturbances (dyspepsia, flatulence) (up to 7%), changes in appetite (6%)</p><p></p><p>Leuprolide:</p><p><b>Very common</b> (10% or more): Nausea/vomiting (25%), altered bowel function (constipation, diarrhea) (14%)</p><p><b>Common</b> (1% to 10%): Changes in appetite (4%)%), GI disturbances (dyspepsia, flatulence) (4%)<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>Leuprolide-Norethindrone:</p><p><b>Very common</b> (10% or more): Vaginitis (up to 15%%), breast changes/pain/tenderness (up to 13%)</p><p><b>Common</b> (1% to 10%): Menstrual disorders (5%)</p><p><b>Frequency not reported</b>: Urinary tract infection</p><p></p><p>Leuprolide:</p><p><b>Very common</b> (10% or more): Vaginitis (20%)</p><p><b>Common</b> (1% to 10%): Breast changes/pain/tenderness (6%), menstrual disorders (2%)<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Leuprolide:</p><p><b>Postmarketing reports</b>: Decreased white blood count<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Leuprolide:</p><p><b>Postmarketing reports</b>: Serious liver injury</p><p>Leuprolide-Norethindrone:</p><p><b>Common</b> (1% to 10%): Elevated SGPT (at least twice the upper limit) (2%), elevated GGT (1.5%)<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Leuprolide-Norethindrone:</p><p><b>Postmarketing reports</b>: Allergic reactions (anaphylactic, rash, urticaria, photosensitivity)<sup>[Ref]</sup></p><h3>Local</h3><p>Leuprolide-Norethindrone:</p><p><b>Common</b> (1% to 10%): Injection site reaction (up to 9%)</p><p></p><p>Leuprolide:</p><p><b>Common</b> (1% to 10%): Injection site reaction (2%)</p><p><b>Postmarketing reports</b>: Localized reactions including induration and abscess at the site of injection<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Leuprolide-Norethindrone:</p><p><b>Very common</b> (10% or more): Weight gain (up to 13%)</p><p><b>Common</b> (1% to 10%): Edema (up to 9%), elevated SGPT (at least twice the upper limit) (2%), elevated GGT (1.5%)</p><p><b>Frequency not reported</b>: Increased total cholesterol (greater than 240 mg/dL), decreased HDL cholesterol (less than 40 mg/dL), increased LDL cholesterol (greater than 160 mg/dL), increased LDL/HDL ratio (greater than 4), increased triglycerides (greater than 200 mg/dL)</p><p></p><p>Leuprolide:</p><p><b>Common</b> (1% to 10%): Weight gain (12%)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Leuprolide:</p><p><b>Postmarketing reports</b>: Spinal fracture, tenosynovitis-like symptoms, symptoms consistent with fibromyalgia<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Leuprolide-Norethindrone:</p><p><b>Very common</b> (10% or more): Headache/migraine (up to 51%), insomnia/sleep disorders (up to 15%), dizziness/vertigo (up to 11%)</p><p><b>Common</b> (1% to 10%): Neuromuscular disorder (leg cramps, paraesthesia) (up to 9%), decreased libido (up to 7%), memory disorder (up to 4%)</p><p></p><p>Leuprolide:</p><p><b>Very common</b> (10% or more): Headache/migraine (65%), insomnia/sleep disorders (31%), dizziness/vertigo (16%), decreased libido (10%)</p><p><b>Common</b> (1% to 10%): Memory disorder (6%), neuromuscular disorder (leg cramps, paraesthesia) (2%)</p><p><b>Postmarketing reports</b>: Pituitary apoplexy, convulsion, peripheral neuropathy, paralysis<sup>[Ref]</sup></p><h3>Other</h3><p>Leuprolide-Norethindrone:</p><p><b>Very common</b> (10% or more): Pain (up to 29%), asthenia (up to 18%)</p><p></p><p>Leuprolide:</p><p><b>Very common</b> (10% or more): Pain (24%), asthenia (18%)</p><h3>Psychiatric</h3><p>Leuprolide-Norethindrone:</p><p><b>Very common</b> (10% or more): Depression/emotional lability (up to 34%), nervousness/anxiety (up to 11%)</p><p></p><p>Leuprolide:</p><p><b>Very common</b> (10% or more): Depression/emotional lability (31%)</p><p><b>Common</b> (1% to 10%): Nervousness/anxiety (8%)</p><p><b>Postmarketing reports</b>: Mood swings, suicidal ideation and attempt<sup>[Ref]</sup></p><h3>Renal</h3><p>Leuprolide-Norethindrone:</p><p><b>Frequency not reported</b>: Renal calculus<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Leuprolide:</p><p><b>Postmarketing reports</b>: Symptoms consistent with an asthmatic process<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Lupaneta Pack (leuprolide-norethindrone)." Abbott Pharmaceutical, Abbott Park, IL. </p><h2>More about Lupaneta Pack (leuprolide / norethindrone)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: sex hormone combinations</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Lupaneta Pack &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Endometriosis</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>